Item 2.02. Results of Operations and Financial Condition.
OnJanuary 10, 2021 ,Emergent BioSolutions Inc. announced preliminary unaudited financial results for 2020 and guidance for 2021. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In addition, the sections entitled "Our business units address a >$50B global market," "Biologics-focused CDMO services add diversification and growth opportunities," "Diversified revenue growth complemented by sustained profitability," "Reconciliation of net income to adjusted EBITDA 2021F and 2020E - 2016," "Our track record of key M&A since 2013," "The growth of CDMO at Emergent" and "Our CDMO business utilizes multiple platform technologies addressing compelling market opportunities" of the corporate slide deck furnished as Exhibit 99.2 are incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
During the week of
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description 99.1 Press release issued by the Company on January 10, 2021. 99.2 Corporate slide deck, dated January 1 1 , 2020. Emergent BioSolutions Inc. Current Report on Form 8-K, dated January 10, 2021 formatted in XBRL (Extensible Business Reporting Language): Cover Page. The instance document does not appear in the Interactive Data File 101 because its XBRL tags are embedded within the Inline XBRL document. Cover Page Interactive Data File (formatted as Inline XBRL and contained 104 in Exhibit 101).
© Edgar Online, source